PrevAKI

  • Research type

    Research Study

  • Full title

    BIOMARKER GUIDED IMPLEMENTATION OF THE CARDIOVASCULAR SURGERY AKI BUNDLE GUIDELINES TO REDUCE THE OCCURRENCE OF AKI IN PATIENTS AFTER CARDIAC SURGERY

  • IRAS ID

    233949

  • Contact name

    Marlies Ostermann

  • Contact email

    Marlies.Ostermann@gstt.nhs.uk

  • Sponsor organisation

    Guy's & St Thomas NHS Foundation Hospital

  • Clinicaltrials.gov Identifier

    NCT03244514

  • Duration of Study in the UK

    3 years, 0 months, 1 days

  • Research summary

    After heart surgery, patients have a high risk of acute kidney failure, also known as acute kidney injury (AKI). At present, there is no cure for AKI, and management is limited to optimising the blood pressure and heart function, correcting dehydration and avoiding medications that could harm the kidneys.

    The aim of this study is to study whether the use of an AKI bundle reduces the incidence of AKI after cardiovascular surgery and is as safe as standard clinical care.

    For this purpose, we plan to randomise (ie. similar to tossing a coin) high risk patients to standard care versus treatment according to a number of official recommendations. We will use a urine test to identify high risk patients.

    As per protocol, patients who agree to participate will have a urine test within 4 hours after heart surgery. If the urine test is normal, no further actions will be taken. If the urine test indicates that they are at high risk of AKI, they will be randomised to either treatment according to a list of official recommendations for prevention for a duration of 12 hours or standard care. Treatment in the intervention group includes the optimisation of blood pressure and heart function, avoidance of harmful drugs and fluid treatment to correct any dehydration.
    All other treatments will be decided by the clinical teams according to departmental practice.

    We will record whether there are important differences between both groups up to 90 days after surgery, including development of AKI, length of stay in hospital, need for dialysis or adverse events.

  • REC name

    South Central - Berkshire Research Ethics Committee

  • REC reference

    18/SC/0445

  • Date of REC Opinion

    28 Sep 2018

  • REC opinion

    Favourable Opinion